Brooklyn ImmunoTherapeutics is a clinical-stage biopharmaceutical company focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Co. is seeking to develop IRX-2, a cytokine-based therapy, to treat patients with cancer. Co. also is exploring opportunities to advance oncology, blood disorder, and monogenic disease therapies using gene-editing and cell therapy technology through a license with Factor Bioscience Limited and through its subsidairies, Novellus, Inc. and Novellus, Ltd.
|
Free BTX Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Hold (2.00 out of 4) 18th percentile
(ranked lower than approx. 82% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |